Company Candel Therapeutics, Inc.

Equities

CADL

US1374041093

Biotechnology & Medical Research

Analysts' Consensus

Business Summary

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Other Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 01:30:00 11/05/2024 am IST			After market 03:49:06 am
9.32 ^USD	-6.52%		9.295	-0.27%

11/04	Sector Update: Health Care Stocks Decline Thursday Afternoon	MT
11/04	Candel Therapeutics Shares Rise After FDA Orphan Drug Designation for Potential Pancreatic Cancer Drug	MT

Candel Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing off-the-shelf multimodal biological immunotherapies that elicit an individualized, systemic anti-tumor immune response to help patients fight cancer. The Company has established two clinical-stage multimodal biological immunotherapy platforms based on novel, genetically modified adenovirus and herpes simplex virus (HSV) gene constructs, respectively. CAN-2409 is the lead product candidate from the adenovirus platform and is in ongoing clinical trials in non-small cell lung cancer (NSCLC), borderline resectable pancreatic cancer, and localized, non-metastatic prostate cancer. CAN-3110 is the lead product candidate from the HSV platform and is in an ongoing investigator-sponsored phase I clinical trial in recurrent high-grade glioma (HGG). Its enLIGHTEN Discovery Platform leverages human biology and advanced analytics to create new viral immunotherapies for solid tumors.

Number of employees: 42

Managers	Title	Age	Since
Paul-Peter Tak CEO	Chief Executive Officer	64	01/20/01
Estuardo Aguilar-Cordova FOU	Founder	66	01/02/01
Charles Schoch DFI	Director of Finance/CFO	39	-
Seshu Tyagarajan CTO	Chief Tech/Sci/R&D Officer	57	02/22/02
Francesca Barone CTO	Chief Tech/Sci/R&D Officer	47	01/20/01
William Nichols CTO	Chief Tech/Sci/R&D Officer	55	12/22/12
Ileen B. Winick HRO	Human Resources Officer	-	01/21/01
Nathan Caffo PRN	Corporate Officer/Principal	55	01/20/01
Susan Stewart LAW	General Counsel	64	01/20/01

Members of the board	Title	Age	Since
Joseph Papa BRD	Director/Board Member	68	08/22/08
Edward Benz BRD	Director/Board Member	78	01/17/01
Paul Manning CHM	Chairman	68	01/18/01
Gary Nabel BRD	Director/Board Member	70	08/22/08
Estuardo Aguilar-Cordova FOU	Founder	66	01/02/01
Paul-Peter Tak CEO	Chief Executive Officer	64	01/20/01
Renee Gaeta BRD	Director/Board Member	42	08/22/08
Diem Nguyen BRD	Director/Board Member	52	15/21/15
Christopher Martell BRD	Director/Board Member	45	01/18/01
Nicoletta Loggia BRD	Director/Board Member	-	07/23/07

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	29,470,076	19,157,342 ( 65.01 %)	0	65.01 %

Name	Equities	%	Valuation
Estuardo Aguilar-Cordova 10.91 %	3,153,815	10.91 %	5 M $
Laura Aguilar 10.49 %	3,032,700	10.49 %	5 M $
Paul Manning 9.949 %	2,877,158	9.949 %	5 M $
Northpond Ventures LLC 6.692 %	1,935,215	6.692 %	3 M $
Sands Capital Ventures LLC 2.807 %	811,737	2.807 %	1 M $
Vanguard Group, Inc. (Subfiler) 1.872 %	541,295	1.872 %	855 246 $
Christopher Martell 1.506 %	435,514	1.506 %	688 112 $
Banor Capital Ltd. 1.379 %	398,826	1.379 %	630 145 $
Fidelity Management & Research Co. LLC 1.032 %	298,384	1.032 %	471 447 $
Geode Capital Management LLC 0.4815 %	139,253	0.4815 %	220 020 $

Candel Therapeutics, Inc.

117 Kendrick Street Suite 450

02494, Needham

http://www.candeltx.com

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

9.32 USD

Average target price

11 USD

Spread / Average Target

+18.03%

Consensus

Estimates Revisions

Company calendar

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Other Biotechnology & Medical Research

	1st Jan change	Capi.
CANDEL THERAPEUTICS, INC.	+534.01%	274M
MODERNA, INC.	+17.96%	44.96B
IQVIA HOLDINGS INC.	+1.17%	42.65B
LONZA GROUP AG	+48.77%	41.85B
CELLTRION, INC.	-4.27%	29.04B
ICON PUBLIC LIMITED COMPANY	+11.42%	26.08B
ALNYLAM PHARMACEUTICALS, INC.	-21.39%	19.03B
BIO-TECHNE CORPORATION	+4.86%	12.75B
MEDPACE HOLDINGS, INC.	+27.29%	12.06B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-3.50%	11.75B

Other Biotechnology & Medical Research